宜明昂科获药监局受理肺动脉高压临床试验申请
4月2日，宜明昂科（01541）发布公告，告知股东及潜在投资者有关公司最新业务发展情况。公告指出，公司已获得中华人民共和国国家药品监督管理局受理IMC-003/IMM72治疗肺动脉高压的临床试验申请。这一进展标志着公司在非肿瘤疾病的临床研究方面取得了里程碑式的成就。
IMC-003/IMM72是一种通过基因改造的新一代激活素受体IIA-Fc型融合蛋白，具有更高的活性及品质。公司拥有IMC-003/IMM72的全球知识产权以及开发和商业化权利，并且截至公告日期，拥有一个包括在中国、美国、日本及欧盟的已授权专利的专利家族。公告同时提醒股东及潜在投资者，公司无法保证能够成功开发或最终上市销售IMC-003/IMM72，建议在买卖公司股份时应谨慎行事。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10